• Verona Pharma PLC VRNA.OQ reported a quarterly adjusted loss of 2 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -32 cents. The mean expectation of seven analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -26 cents to -2 cents per share.

• Revenue was $76.26 million​; analysts expected $53.37 million.

• Verona Pharma PLC's reported EPS for the quarter was a loss of 2 cents​.

• The company reported a quarterly loss of $16.32 million.

• Verona Pharma PLC shares had risen by 8.4% this quarter and gained 48.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 14.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Verona Pharma PLC is $80.00

This summary was machine generated from LSEG data April 29 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)